Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 688 results
Found 688 results.


Erlandson KM, Fiorillo S, Masawi F, et al. "Antiretroviral initiation is associated with increased skeletal muscle area and fat content." AIDS. 2017;31(13):1831-1838.
Erlandson KM, Wu K, Koletar SL, et al. "Association Between Frailty and Components of the Frailty Phenotype With Modifiable Risk Factors and Antiretroviral Therapy." J. Infect. Dis.. 2017;215(6):933-937.
George V, Harrison L, Roach M, et al. "Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome." J. Infect. Dis.. 2017;216(9):1159-1163.
Kiser JJ, Lu D, Rosenkranz SL, et al. "Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s." Drugs R D. 2017;17(4):557-567.
Gupta SK, Yeh E, Kitch DW, et al. "Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s." J. Antimicrob. Chemother.. 2017;72(7):2042-2048.
Macatangay BJ, Yang M, Sun X, et al. "Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217." J. Acquir. Immune Defic. Syndr.. 2017;75(1):137-141.
Judge CJ, Kostadinova L, Sherman KE, et al. "CD56NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections." J. Leukoc. Biol.. 2017;102(1):171-184.
Bhagwat P, Ofotokun I, McComsey GA, et al. "Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes." Antivir. Ther. (Lond.). 2017;22(7):577-586.
Gay CL, Bosch RJ, Ritz J, et al. "Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2017;215(11):1725-1733.
Podany AT, Scarsi KK, Fletcher CV. "Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors." Clin Pharmacokinet. 2017;56(1):25-40.
Greer AE, San Ou S-, Wilson E, et al. "Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052." J. Acquir. Immune Defic. Syndr.. 2017;76(4):388-393.
Johs NA, Wu K, Tassiopoulos K, et al. "Disability Among Middle-Aged and Older Persons With Human Immunodeficiency Virus Infection." Clin. Infect. Dis.. 2017;65(1):83-91.
Bednasz CJ, Venuto CS, Ma Q, et al. "Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants." Ther Drug Monit. 2017;39(6):596-603.
Nixon DE, Bosch RJ, Chan ES, et al. "Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5." J Clin Lipidol. 2017;11(1):61-69.
Manasa J, Varghese V, Pond SLKosakovs, et al. "Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors." Sci Rep. 2017;7(1):11559.
Tassiopoulos K, Abdo M, Wu K, et al. "Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults." AIDS. 2017;31(16):2287-2294.
Qi L, Sun Y, Gilbert PB. "Generalized semiparametric varying-coefficient model for longitudinal data with applications to adaptive treatment randomizations." Biometrics. 2017;73(2):441-451.
Celum C, Hong T, Cent A, et al. "Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study." J. Infect. Dis.. 2017;215(6):907-910.
Carlton-Smith C, Holmes JA, Naggie S, et al. "IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR." J. Viral Hepat.. 2017.
Neto MF, Butzler MA, Reed JL, et al. "Immiscible phase filter extraction and equivalent amplification of genotypes 1-6 of hepatitis C RNA: The building blocks for point-of-care diagnosis." J. Virol. Methods. 2017;248:107-115.
Coban H, Robertson K, Smurzynski M, et al. "Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen." AIDS. 2017;31(11):1565-1571.
Park YJeong, Etemad B, Ahmed H, et al. "Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption." Pathog Immun. 2017;2(3):431-445.
Badal-Faesen S, Firnhaber C, Kendall MA, et al. "Impact of Larger Sputum Volume on XpertMTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis." J Clin Med. 2017;6(8).
Parker RA, Rabideau DJ, Sax PE, et al. "Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study." Clin. Infect. Dis.. 2017;64(11):1612-1614.
Erlandson KM, Kitch D, C Wester W, et al. "The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus Infection." Clin. Infect. Dis.. 2017;65(12):2042-2049.
Venuto CS, Lim J, Messing S, Hunt PW, McComsey GA, Morse GD. "Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s." Antivir. Ther. (Lond.). 2017.
Erlandson KM, Fiorillo SP, Cardoso SWagner, et al. "Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation." AIDS Res. Hum. Retroviruses. 2017;33(9):929-934.
Tam E, Luetkemeyer AF, Mantry PS, et al. "Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials." Liver Int.. 2017.